98%
921
2 minutes
20
Objective: Missed diagnosis of genetic conditions is a persistent challenge in clinical care, particularly for familial hypercholesterolemia (FH), hereditary breast and ovarian cancer (HBOC), and Lynch syndrome-conditions designated by the U.S. Centers for Disease Control and Prevention (CDC) as Tier 1 genomic applications. This scoping review summarizes evidence on the use of electronic health record (EHR)-based algorithms to identify individuals with these conditions.
Materials And Methods: We conducted a scoping review using the JBI Manual for Evidence Synthesis and reported results according to PRISMA-ScR guidelines. We searched Ovid MEDLINE, Embase, and Web of Science through October 2024 for studies evaluating EHR-based algorithms to identify individuals with FH, HBOC, or Lynch syndrome. Eligible studies addressed (1) performance of algorithms in detecting clinically or genetically confirmed cases or (2) outcomes from the implementation of algorithms in unselected populations with follow-up to identify new diagnoses.
Results: Of 598 articles screened, 22 met inclusion criteria. Most studies (20/22) focused on FH. Fourteen FH studies assessed algorithm performance, and 7 reported prospective implementation. FH algorithm performance varied widely (AUROC range 0.78-0.95), with machine learning models outperforming rule-based approaches. Implementation studies reported positive predictive values ranging from 11% to 67%. Only two studies addressed HBOC or Lynch syndrome, both using rules-based algorithms with limited sensitivity.
Discussion: Machine learning models consistently outperform rules-based algorithms relying on clinical criteria, but limited evidence exists for HBOC and Lynch syndrome.
Conclusions: Early identification of CDC Tier 1 genetic conditions through EHR-based screening algorithms holds promise but will require both technical and implementation advances to realize improved patient care and outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jamia/ocaf140 | DOI Listing |
J Am Med Inform Assoc
August 2025
VA Boston Healthcare System, Boston, MA, 02130, United States.
Objective: Missed diagnosis of genetic conditions is a persistent challenge in clinical care, particularly for familial hypercholesterolemia (FH), hereditary breast and ovarian cancer (HBOC), and Lynch syndrome-conditions designated by the U.S. Centers for Disease Control and Prevention (CDC) as Tier 1 genomic applications.
View Article and Find Full Text PDFOncol Rev
July 2025
Medical University Varna, Department of Oncology, Varna, Bulgaria.
This study presents a 5-year retrospective analysis of genetic counseling (GC) services for hereditary cancer syndromes (HCS) at a single center in Bulgaria. The aim is to describe the demographic and epidemiological characteristics of patients seeking GC, the uptake of genetic testing, and the spectrum of identified pathogenic variants. The results highlight an increasing trend in GC utilization.
View Article and Find Full Text PDFEur J Hum Genet
July 2025
Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Observational studies suggest that direct contact from healthcare to at-risk relatives may increase genetic counselling (GC) uptake as compared to family-mediated risk disclosure, but randomised controlled trials (RCTs) are lacking. This study assessed whether the offer of direct letters to relatives at risk of hereditary breast and ovarian cancer (HBOC) or Lynch syndrome increases GC uptake compared to family-mediated communication alone. Between 2020 and 2023, probands were randomly assigned to family-mediated disclosure (control) or family-mediated disclosure plus the offer of sending direct letters to at-risk relatives (intervention).
View Article and Find Full Text PDFGenes (Basel)
June 2025
Medical Genetics Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy.
: The national guidelines, informed by evidence from the National Institutes of Health (NIH), define the criteria for genetic testing of BRCA1/2 and other genes associated with Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome (LS). When a germline pathogenic variant (PV) is identified in an index case, clinical recommendations advise informing at-risk relatives about the availability of predictive genetic testing, as early identification of carriers allows for timely implementation of preventive measures. : This retrospective observational study examined data collected between 2017 and 2024 at the Medical Genetics Unit of the "Renato Dulbecco" University Hospital in Catanzaro, Italy.
View Article and Find Full Text PDFGenes (Basel)
April 2025
Cancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid-Spanish National Research Council (UVa-CSIC), C/Sanz y Forés 3, 47003 Valladolid, Spain.
Background And Objectives: Despite the well-established role of the BRCA and mismatch repair (MMR) genes in DNA damage repair pathways, a substantial proportion of familial cancer cases still lack pathogenic variants in those genes. Next Generation Sequencing (NGS) panels have emerged as a powerful tool to identify hereditary cancer at-risk individuals and subsequently provide them with accurate management.
Materials And Methods: Families harbouring PVs in , , , and were identified by analysing a cancer-predisposing genes panel using Ion S5 system technology.